Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 10:44am EST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07:01a REGENERON PHARMACEUTICALS : Biotech Stocks Under Scanner -- Kite Pharma, BioPhar..
01/12 REGENERON PHARMACEUTICALS : Findings from Regeneron Pharmaceuticals Provide New ..
01/12 REGENERON PHARMACEUTICALS : Hires Jay Markowitz, M.D., as Senior Vice President ..
01/10 REGENERON PHARMACEUTICALS,INC. (NASD : REGN) Files An 8-K Results of Operations ..
01/09 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09 REGENERON PHARMACEUTICALS INC : Results of Operations and Financial Condition, R..
01/09 SANOFI : and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent L..
01/06DJSanofi Investors Count Cost of Praluent Ruling -- Update
01/06 NASDAQ 100 MOVERS : Regn, amgn
01/06 S&P 500 MOVERS : Regn, amgn
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/09 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03:40p HEALTHCARE SUMMIT ON THE EVE OF TRUM : Milligan's Mea Culpa
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/19 Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely
01/19 ONE STEP CLOSER TO FINANCIAL FREEDOM : My 2016 Income Review
01/14 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Srg, ozm, rvp
Advertisement
Financials ($)
Sales 2016 4 929 M
EBIT 2016 1 858 M
Net income 2016 892 M
Finance 2016 836 M
Yield 2016 -
P/E ratio 2016 46,97
P/E ratio 2017 37,54
EV / Sales 2016 7,59x
EV / Sales 2017 6,44x
Capitalization 38 239 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 435 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Damis Yancopoulos President & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Charles A. Baker Independent Class III Director
Michael S. Brown Independent Class I Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-3.47%38 239
AMGEN, INC.4.45%115 062
GILEAD SCIENCES, INC.-1.28%93 553
CELGENE CORPORATION-2.97%87 334
ACTELION LTD1.18%23 977
VERTEX PHARMACEUTICALS..10.49%20 182
More Results